Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Volume: 380, Issue: 12, Pages: 1116 - 1127
Published: Mar 21, 2019
Abstract
The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was...
Paper Details
Title
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Published Date
Mar 21, 2019
Volume
380
Issue
12
Pages
1116 - 1127
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History